

CASE STUDY

Patient Journey: Insurance Coverage & Payer Switch

Challenge

Schizophrenia is a complex and costly mental illness. While antipsychotic (AP) medications are the cornerstone of treatment to reduce disease severity and mitigate relapse, the patient's ability to acquire medication due to cost and insurance coverage may influence adherence.


Method

We analyzed treatment patterns, health care resource utilization and costs for patients with schizophrenia who switched from commercial to Medicaid insurance coverage using STATinMED RWD Insights, all-payer medical and pharmacy claims.

A Closer Look

Of approximately 40,000 patients:

- 30% remained on commercial insurance
- 70% switched payer to Medicaid



There was more evidence of access to AP medications for patients after switching.

Increases Associated with Transition to Medicaid

Inpatient

Hospital admissions

Longer length of stay

Outpatient

Average # of visits

of community behavioral health center visits

Utilization Management Practice Impact

Medicaid: Many reasons for AP rejection (e.g., prior authorization)



Key Insights

Transition to Medicaid may increase HCRU; despite increase in utilization, costs were not impacted

Overall, cost of care before and after switch was not impacted; which may have been due to lower reimbursement with Medicaid vs commercial coverage.

Access to care and treatment may change as patients transition from commercial to Medicaid coverage.

About STATinMED

Our approach and insights are foremost in the industry based on hundreds of combined experience years and 1000+ peer-reviewed publications in dozens of therapeutic areas.



It's what we do best with RWD.

STATinMED.com | info@STATinMED.com